Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor

BACKGROUND: Ticagrelor (TCG) is used to inhibit platelet aggregation in patients with acute coronary syndrome, but its poor solubility and low bioavailability limit its in vivo efficacy. The purpose of this study was to manufacture an optimized TCG-loaded self-microemulsifying drug delivery system (...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Young-Guk, Byeon, Jin-Ju, Wang, Miao, Huh, Hyun Wook, Son, Gi-Ho, Jeon, Sung-Hoon, Bang, Ki-Hyun, Kim, Sung-Jin, Lee, Hye-Jin, Lee, Hong-Ki, Cho, Cheong-Weon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391151/
https://www.ncbi.nlm.nih.gov/pubmed/30863054
http://dx.doi.org/10.2147/IJN.S190426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391151/
https://www.ncbi.nlm.nih.gov/pubmed/30863054
http://dx.doi.org/10.2147/IJN.S190426

Ejemplares similares